Fwd: Breast tumor metastasis: analysis via proteomic profiling.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: Breast tumor metastasis: analysis via proteomic profiling.
To: mesothelioma77@gmail.com


[1]Expert Rev Proteomics. 2008 Jun; 5(3): 457-67
Goodison S, Urquidi V

The ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and, to date, they predict individual outcomes poorly. The ongoing development of high-throughput proteomic profiling technologies is opening new avenues for the investigation of cancer and, through application in tissue-based studies and animal models, will facilitate the identification of molecular signatures that are associated with breast tumor cell phenotype. The appropriate use of these approaches has the potential to provide efficient biomarkers, and to improve our knowledge of tumor biology. This, in turn, will enable the development of targeted therapeutics aimed at ameliorating the lethal dissemination of breast cancer. In this review, we focus on the accumulating proteomic signatures of breast tumor progression, particularly those that correlate with the occurrence of distant metastases, and discuss some of the expected future developments in the field.



___
Source: http://www.hubmed.org/display.cgi?uids=18532913
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Malignant hematopoietic cell lines: In vitro models for the study of Waldenström's macroglobulinemia.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: Malignant hematopoietic cell lines: In vitro models for the study of Waldenström's macroglobulinemia.
To: mesothelioma77@gmail.com


[1]Leuk Res. 2008 Jun 2;
Drexler HG, Macleod RA

Model cell lines are essential tools for investigating the biology and therapeutics of cancer. Approximately 1500 human hematopoietic neoplastic cell lines have been described, covering most major disease entities. Waldenström's macroglobulinemia (WM) is a rare incurable hematological neoplasm from which only three cell lines have been derived. Mindful that candidate tumor cell lines sometimes arise spuriously by viral immortalization of bystander cells, we review the extent to which WM cell lines portray established disease features in vitro. At closer inspection, it seems that none convincingly displays morphological, immunophenotypic, genotypic or biological features characteristic of WM. Rather it appears that two cell lines (WM1 and BCWM.1) are most probably Epstein-Barr virus-immortalized B-lymphoblastoid cell lines, derived from bystander B-cells. The third cell line (WSU-WM) carries the most common cytogenetic hallmark of Burkitt lymphoma, namely t(8;14)(q24;q32), while none have been shown to carry chromosome 6 deletions recently demonstrated as indicative of disease progression in this entity. In summary, although three WM cell lines are currently used as in vitro models, none convincingly pass muster.



___
Source: http://www.hubmed.org/display.cgi?uids=18533260
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc